Cargando…

Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a

Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy....

Descripción completa

Detalles Bibliográficos
Autores principales: Itoh, Masatsune, Okajima, Michiko, Kittaka, Yuko, Yachie, Akihiro, Wada, Taizo, Saikawa, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043659/
https://www.ncbi.nlm.nih.gov/pubmed/35497370
http://dx.doi.org/10.1016/j.bonr.2022.101569
_version_ 1784694931017695232
author Itoh, Masatsune
Okajima, Michiko
Kittaka, Yuko
Yachie, Akihiro
Wada, Taizo
Saikawa, Yutaka
author_facet Itoh, Masatsune
Okajima, Michiko
Kittaka, Yuko
Yachie, Akihiro
Wada, Taizo
Saikawa, Yutaka
author_sort Itoh, Masatsune
collection PubMed
description Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy. We report two unrelated cases with PHP1a who developed tertiary hyperparathyroidism (HPT). Molecular analyses of the GNAS gene identified a previously known heterozygous 4-bp deletion (c. 565_568delGACT) in exon 7 in case 1 and a novel heterozygous missense mutation (p.Lys233Glu) in exon 9 in case 2. Both patients developed tertiary HPT associated with hyperfunctioning parathyroid glands during long-term treatment of hypocalcemia. Case 1 had severe osteoporosis and underwent parathyroidectomy. Case 2 was asymptomatic with no evidence of bone diseases associated with tertiary HPT. PHP1a patients are at risk of developing tertiary HPT and should be treated with sufficient doses of calcium and vitamin D to achieve serum PTH levels within the mid - normal to double the upper limit of the normal range, regardless of serum calcium levels.
format Online
Article
Text
id pubmed-9043659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90436592022-04-28 Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a Itoh, Masatsune Okajima, Michiko Kittaka, Yuko Yachie, Akihiro Wada, Taizo Saikawa, Yutaka Bone Rep Full Length Article Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy. We report two unrelated cases with PHP1a who developed tertiary hyperparathyroidism (HPT). Molecular analyses of the GNAS gene identified a previously known heterozygous 4-bp deletion (c. 565_568delGACT) in exon 7 in case 1 and a novel heterozygous missense mutation (p.Lys233Glu) in exon 9 in case 2. Both patients developed tertiary HPT associated with hyperfunctioning parathyroid glands during long-term treatment of hypocalcemia. Case 1 had severe osteoporosis and underwent parathyroidectomy. Case 2 was asymptomatic with no evidence of bone diseases associated with tertiary HPT. PHP1a patients are at risk of developing tertiary HPT and should be treated with sufficient doses of calcium and vitamin D to achieve serum PTH levels within the mid - normal to double the upper limit of the normal range, regardless of serum calcium levels. Elsevier 2022-04-14 /pmc/articles/PMC9043659/ /pubmed/35497370 http://dx.doi.org/10.1016/j.bonr.2022.101569 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Full Length Article
Itoh, Masatsune
Okajima, Michiko
Kittaka, Yuko
Yachie, Akihiro
Wada, Taizo
Saikawa, Yutaka
Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title_full Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title_fullStr Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title_full_unstemmed Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title_short Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
title_sort tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043659/
https://www.ncbi.nlm.nih.gov/pubmed/35497370
http://dx.doi.org/10.1016/j.bonr.2022.101569
work_keys_str_mv AT itohmasatsune tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a
AT okajimamichiko tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a
AT kittakayuko tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a
AT yachieakihiro tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a
AT wadataizo tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a
AT saikawayutaka tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a